Work

Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis

Year: 2023

Type: article

Source: Clinical Gastroenterology and Hepatology

DOI: 10.1016/j.cgh.2023.01.018

Authors: Mohammad Shadab Siddiqui, Deven Parmar, Farheen Sheikh, Shiv Kumar Sarin, Laura Cisneros, Samer Gawrieh, Taufik Momin, Ajay Duseja, Arun J. Sanyal

Institutions: Virginia Commonwealth University, Zydus Therapeutics Inc. (United States), Institute of Liver and Biliary Sciences, Hospital Christus Muguerza Alta Especialidad, Indiana University School of Medicine, Post Graduate Institute of Medical Education and Research

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Novartis, Gilead Sciences, Novartis Pharmaceuticals Corporation

OpenAlex ID: W4318561977

FWCI: 8.547

Cites: 31

Cited by: 43

Related to: 10